144 related articles for article (PubMed ID: 19228633)
1. Bezafibrate for an inborn mitochondrial beta-oxidation defect.
Bonnefont JP; Bastin J; Behin A; Djouadi F
N Engl J Med; 2009 Feb; 360(8):838-40. PubMed ID: 19228633
[No Abstract] [Full Text] [Related]
2. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
Bastin J; Bonnefont JP; Djouadi F; Bresson JL
J Inherit Metab Dis; 2015 Mar; 38(2):371-2. PubMed ID: 25310995
[No Abstract] [Full Text] [Related]
3. No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.
Ørngreen MC; Vissing J; Laforét P
J Inherit Metab Dis; 2015 Mar; 38(2):373-4. PubMed ID: 25331908
[No Abstract] [Full Text] [Related]
4. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency.
Bonnefont JP; Bastin J; Laforêt P; Aubey F; Mogenet A; Romano S; Ricquier D; Gobin-Limballe S; Vassault A; Behin A; Eymard B; Bresson JL; Djouadi F
Clin Pharmacol Ther; 2010 Jul; 88(1):101-8. PubMed ID: 20505667
[TBL] [Abstract][Full Text] [Related]
5. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
Ørngreen MC; Madsen KL; Preisler N; Andersen G; Vissing J; Laforêt P
Neurology; 2014 Feb; 82(7):607-13. PubMed ID: 24453079
[TBL] [Abstract][Full Text] [Related]
7. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency.
Yasuno T; Osafune K; Sakurai H; Asaka I; Tanaka A; Yamaguchi S; Yamada K; Hitomi H; Arai S; Kurose Y; Higaki Y; Sudo M; Ando S; Nakashima H; Saito T; Kaneoka H
Biochem Biophys Res Commun; 2014 May; 448(2):175-81. PubMed ID: 24780397
[TBL] [Abstract][Full Text] [Related]
9. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
Djouadi F; Bastin J
J Inherit Metab Dis; 2008 Apr; 31(2):217-25. PubMed ID: 18392740
[TBL] [Abstract][Full Text] [Related]
10. Carnitine-acylcarnitine translocase deficiency: Two neonatal cases with common splicing mutation and in vitro bezafibrate response.
Vatanavicharn N; Yamada K; Aoyama Y; Fukao T; Densupsoontorn N; Jirapinyo P; Sathienkijkanchai A; Yamaguchi S; Wasant P
Brain Dev; 2015 Aug; 37(7):698-703. PubMed ID: 25459972
[TBL] [Abstract][Full Text] [Related]
11. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.
Djouadi F; Bonnefont JP; Thuillier L; Droin V; Khadom N; Munnich A; Bastin J
Pediatr Res; 2003 Oct; 54(4):446-51. PubMed ID: 12840153
[TBL] [Abstract][Full Text] [Related]
12. Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?
Djouadi F; Aubey F; Schlemmer D; Gobin S; Laforet P; Wanders RJ; Strauss AW; Bonnefont JP; Bastin J
J Inherit Metab Dis; 2006; 29(2-3):341-2. PubMed ID: 16763897
[TBL] [Abstract][Full Text] [Related]
13. First Japanese Case of Carnitine Palmitoyltransferase II Deficiency with the Homozygous Point Mutation S113L.
Shima A; Yasuno T; Yamada K; Yamaguchi M; Kohno R; Yamaguchi S; Kido H; Fukuda H
Intern Med; 2016; 55(18):2659-61. PubMed ID: 27629963
[TBL] [Abstract][Full Text] [Related]
14. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
Lund M; Andersen KG; Heaton R; Hargreaves IP; Gregersen N; Olsen RKJ
Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166100. PubMed ID: 33549744
[TBL] [Abstract][Full Text] [Related]
15. Serious pregnancy complications in a patient with previously undiagnosed carnitine palmitoyltransferase 1 deficiency.
Ylitalo K; Vänttinen T; Halmesmäki E; Tyni T
Am J Obstet Gynecol; 2005 Jun; 192(6):2060-2. PubMed ID: 15970898
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiological approach to carnitine palmitoyltransferase II deficiencies.
Demaugre F; Bonnefont JP; Brivet M; Cepanec C; Pollitt RJ; Priestley BL; Saudubray JM; Leroux JP
Prog Clin Biol Res; 1992; 375():301-8. PubMed ID: 1438375
[No Abstract] [Full Text] [Related]
17. Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
Shiraishi H; Yamada K; Egawa K; Ishige M; Ochi F; Watanabe A; Kawakami S; Kuzume K; Watanabe K; Sameshima K; Nakamagoe K; Tamaoka A; Asahina N; Yokoshiki S; Kobayashi K; Miyakoshi T; Oba K; Isoe T; Hayashi H; Yamaguchi S; Sato N
Brain Dev; 2021 Feb; 43(2):214-219. PubMed ID: 32798077
[TBL] [Abstract][Full Text] [Related]
18. [Mitochondrial beta-oxidation defects].
Woldseth B; Rootwelt T
Tidsskr Nor Laegeforen; 2006 Mar; 126(6):756-9. PubMed ID: 16541168
[TBL] [Abstract][Full Text] [Related]
19. In vivo stable isotope studies in three patients affected with mitochondrial fatty acid oxidation disorders: limited diagnostic use of 1-13C fatty acid breath test using bolus technique.
Jakobs C; Kneer J; Martin D; Boulloche J; Brivet M; Poll-The BT; Saudubray JM
Eur J Pediatr; 1997 Aug; 156 Suppl 1():S78-82. PubMed ID: 9266222
[TBL] [Abstract][Full Text] [Related]
20. Intestinal pseudo-obstruction as a manifestation of impaired mitochondrial fatty acid oxidation.
Gilbert J; Ibdah JA
Med Hypotheses; 2005; 64(3):586-9. PubMed ID: 15617873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
